NextCure, Inc.

NextCure Inc. (NASDAQ:NXTC) on Tuesday agreed to merge with privately held biotechnology company Avere Therapeutics in an all-stock transaction that will take Avere public while providing $320 million in financing to advance its lead oral IL-23 therapy, AVR-001.

benzinga.com - 2026-07-14 14:09:03

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) PR Newswire

gurufocus.com - 2026-07-14 14:00:00

NEW YORK, July 14, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating NextCure, Inc. (NASDAQ: NXTC ) related to its merger with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company.

prnewswire.com - 2026-07-14 13:34:00

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire

gurufocus.com - 2026-07-14 12:00:00

MILWAUKEE, July 14, 2026 /PRNewswire/ -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avere Therapeutics. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-07-14 11:41:00

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. Upon closing of the pr

gurufocus.com - 2026-07-14 11:00:00

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company.Halper Sadeh encourages NextCure shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or.

businesswire.com - 2026-07-14 10:59:00

Avere Therapeutics' lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy

globenewswire.com - 2026-07-14 06:00:00

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.

zacks.com - 2026-07-08 09:35:14

BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release).

globenewswire.com - 2026-06-04 08:00:00

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript

seekingalpha.com - 2026-06-02 17:31:51

55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC NextCure to host virtual Key Opinion Leader (KOL) Event June 2, 2026 at 8 AM ET BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd.

globenewswire.com - 2026-06-01 08:00:00

BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported first quarter 2026 financial results.

globenewswire.com - 2026-05-07 16:05:00

Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md. , May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co.

globenewswire.com - 2026-05-04 07:05:00

BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.

globenewswire.com - 2026-05-04 07:05:00

Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026

globenewswire.com - 2026-04-21 10:15:00